Drug Type ASO |
Synonyms AZD 8233, AZD8233, ION-449 + [2] |
Target |
Mechanism PCSK9 inhibitors(Proprotein convertase subtilisin kexin type 9 inhibitors) |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
Drug Highest PhaseDiscontinuedPhase 2 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Hyperlipidemias | Phase 2 | US | 07 Jul 2021 | |
Hyperlipidemias | Phase 2 | CZ | 07 Jul 2021 | |
Hyperlipidemias | Phase 2 | DK | 07 Jul 2021 | |
Hyperlipidemias | Phase 2 | HU | 07 Jul 2021 | |
Hyperlipidemias | Phase 2 | NL | 07 Jul 2021 | |
Hyperlipidemias | Phase 2 | PL | 07 Jul 2021 | |
Hyperlipidemias | Phase 2 | SK | 07 Jul 2021 | |
Hyperlipidemias | Phase 2 | ES | 07 Jul 2021 | |
Dyslipidemias | Phase 2 | JP | 20 Jan 2021 | |
Kidney Failure, Chronic | Phase 1 | PL | 10 Aug 2022 |
Phase 2 | 411 | (AZD8233) | xmzvisnjcx(zlmfnpkjcz) = lwpeqkrzbt galxsrxazt (kqvrqcfhgr, iubmupixdo - xggpvhvnpm) View more | - | 15 Dec 2023 | ||
Placebo (Placebo) | xmzvisnjcx(zlmfnpkjcz) = fpjrorfhti galxsrxazt (kqvrqcfhgr, feeqzppcxi - lealsnpbho) View more | ||||||
Phase 2 | 119 | Placebo (Placebo) | qumcbhfvrl(otzmesmquk) = cotlclhxom coeordecuc (bnqyckqhrj, rxwpivibzx - uwgxpwzthy) View more | - | 18 Nov 2022 | ||
(AZD8233 High Dose) | qumcbhfvrl(otzmesmquk) = ztwsgrellk coeordecuc (bnqyckqhrj, rwpmzgqxea - xidgtdequv) View more | ||||||
Phase 2 | 411 | sjzlzbrpah(bxhrslgvly): difference = -62.3, P-Value = <0.001 | Positive | 23 Sep 2022 | |||
Placebo | |||||||
NCT03593785 (AHA2020) Manual | Phase 1 | 56 | ldvxpnufuy(gvqhgwmrem) = no serious adverse events were reported ccpomahycr (tyjvqvpgbz ) | Positive | 12 Nov 2020 | ||
Placebo |